- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Example 1 [WO2011139951 A1]  | JNJ42165279
Compound class: Synthetic organic
Comment: JNJ-42165279 is an investigational, covalent and selective inhibitor of fatty acid amide hydrolase (FAAH) . Preclinical test findings are reported in , with the conclusion that the favourable ADME and pharmacodynamic profiles of JNJ-42165279 supported it being progressed to clinical trial.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Janero DR, Vadivel SK, Makriyannis A. (2009)
Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies.
Int Rev Psychiatry, 21 (2): 122-33. [PMID:19367506]
2. Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, Webb M, Karbarz M, Scott BP, Wilson SJ et al.. (2015)
Preclinical Characterization of the FAAH Inhibitor JNJ-42165279.
ACS Med Chem Lett, 6 (12): 1204-8. [PMID:26713105]
3. Keith JM, Liu J. (2011)
Modulators of fatty acid amide hydrolase.
Patent number: WO2011139951 A1. Assignee: Janssen Pharmaceutica Nv. Priority date: 03/05/2010. Publication date: 10/11/2011.
4. Pertwee RG. (2014)
Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.
Proc Nutr Soc, 73 (1): 96-105. [PMID:24135210]
5. Sałaga M, Sobczak M, Fichna J. (2014)
Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.
Eur J Pharm Sci, 52: 173-9. [PMID:24275607]